Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
Hines JB, Cameron RB, Esposito A, Kim L, Porcu L, Nuccio A, Viscardi G, Ferrara R, Veronesi G, Forde PM, Taube J, Vokes E, Bestvina CM, Dolezal JM, Sacco M, Monteforte M, Cascone T, Garassino MC, Torri V.
Hines JB, et al. Among authors: cameron rb.
J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117-5. doi: 10.1016/j.jtho.2024.03.010. Online ahead of print.
J Thorac Oncol. 2024.
PMID: 38461929
Free article.